The Plateau Arc: When You're Stronger but the Fat Loss Stops

Every training arc has a point where what worked before stops being enough. The first months of a cut feel like momentum: the scale moves, clothes fit differently, energy is decent. Then, often without any change in effort, it stalls.

That stall is one of the most frustrating experiences in fitness—and one of the best understood in physiology.

Why the first pounds often feel easier

Early weight loss includes more than fat. Reducing food intake, especially carbohydrate, lowers stored glycogen in muscle and liver, and glycogen is stored with water. Less food in the digestive tract and lower sodium intake also shift the scale. That is why the first week or two can look dramatic and then slow down even when fat loss continues at a steady pace.

None of that means early progress was fake. It means the scale mixes several signals, and the fastest ones burn out first.

A smaller body burns less energy

As body mass falls, the energy needed to maintain and move that body falls too. Beyond that expected drop, studies of people after weight loss often show energy expenditure lower than predicted from the new body size alone—a phenomenon called adaptive thermogenesis (Rosenbaum & Leibel, 2010). Evidence level — human physiology studies: metabolic adaptation is real. What it does not mean: that your metabolism is "broken" or that fat loss becomes impossible. The size of the effect varies and is usually smaller than internet forums suggest.

NEAT: the movement you don't notice losing

Non-exercise activity thermogenesis—NEAT—is the energy spent on everything that isn't formal exercise: walking to the car, fidgeting, standing, household tasks. In a classic overfeeding study, differences in NEAT explained much of why some people gained less fat than others (Levine et al., Science 1999).

The same system can work against you during a diet. When energy is low, many people move less without noticing: they sit more, pace less, take the lift. A consistent daily step habit makes that drift visible and is one of the simplest plateau checks available.

Hunger can push back

In a well-known study, people who lost weight on a very-low-energy diet still showed changes in appetite-related hormones—including higher ghrelin and lower leptin, peptide YY and other satiety signals—a year later, along with increased hunger (Sumithran et al., NEJM 2011). Evidence level — human study, specific diet: the body defends against weight loss partly through appetite. That helps explain why holding a deficit gets harder over time even when motivation is high.

Strength progress and fat loss are different scoreboards

Lifters can keep adding weight to the bar while the scale stalls, and that is not a contradiction. Strength depends heavily on skill and the nervous system, not just muscle size. Water and glycogen can mask fat loss for weeks. A lifter who is recomposing—slowly losing fat while holding or gaining muscle—may see waist measurements fall and strength hold with little change in body weight.

Before calling it a plateau, look at several weeks of data: average weight, waist, photos, lifts and how clothes fit.

Sleep, stress and recovery

In a small randomized crossover study, two nights of restricted sleep lowered leptin, raised ghrelin and increased reported hunger and appetite (Spiegel et al., Ann Intern Med 2004). Poor sleep also makes training feel harder and nudges food choices toward convenience.

Stress works in similar ways: it affects sleep, appetite, motivation and how much structure people can keep. These aren't magical explanations for every plateau, but they are common, measurable and often overlooked.

The incretin era

Incretins are gut hormones released after eating. Two are central to this story:

• GLP-1 (glucagon-like peptide-1) increases insulin release when glucose is high, slows stomach emptying and acts on the brain to reduce appetite.
• GIP (glucose-dependent insulinotropic polypeptide) also stimulates insulin release and appears to influence fat tissue and appetite signalling.
• Glucagon is not an incretin, but glucagon-receptor activity increases energy expenditure and affects liver fat metabolism.

Researchers are studying combinations because each pathway contributes something different. Approved medicines: semaglutide, a GLP-1 receptor agonist, produced a mean weight reduction of about 15% over 68 weeks versus about 2% with placebo in adults with obesity (STEP 1, NEJM 2021). Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced mean reductions of up to about 21% at 72 weeks (SURMOUNT-1, NEJM 2022). Both are FDA-approved for specific indications and populations, with prescribing information that lists known risks such as gastrointestinal effects, gallbladder problems and pancreatitis.

Part of the weight lost with these medicines is lean mass, which is one reason resistance training and protein remain relevant even when medication is part of someone's care.

What retatrutide research is actually studying

Retatrutide is an investigational single molecule that activates GIP, GLP-1 and glucagon receptors. You may see it called "GLP-3" online; that is informal marketing shorthand, not a real hormone or receptor class.

In a 48-week Phase 2 trial of 338 adults with obesity, the highest doses produced mean weight reductions of about 24% versus about 2% with placebo (Jastreboff et al., NEJM 2023). Gastrointestinal side effects were common and dose-related, and heart rate increased at higher doses. Evidence level — one Phase 2 trial in people with obesity. The manufacturer has since announced additional Phase 3 results; those are sponsor-reported until published in peer-reviewed form.

Regulatory status as of 26 September 2026: retatrutide is not FDA-approved. It remains investigational, and research-labelled products sold online are not the same as the material tested in clinical trials. Findings in people with obesity also cannot be assumed to apply to leaner, trained lifters looking for a faster cut. We cover the trial data in more detail in Beyond the Scale.

This article does not provide dosing, preparation, cycling, stacking or purchasing information.

A plateau is data, not defeat

A stall is feedback about the current system—how much you move, eat, sleep and recover—not proof that you've failed. The useful response is usually an audit, not a panic: check your steps, your consistency, your sleep, your trends over several weeks. Sometimes the right move is a planned maintenance phase to recover before the next push.

Stories don't end at the plateau. They change strategy. And for many lifters, the next thing that goes wrong isn't the scale—it's the body asking for recovery.